This is a news story, published by Yahoo, that relates primarily to U.S. Food and Drug Administration news.
For more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Yahoo, you can click here:
more news from YahooOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
colorectal cancer. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Bristol Myers news, Mirati Therapeutics news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Bristol Myers SquibbReuters
•81% Informative
U.S. Food and Drug Administration approves Bristol Myers Squibb's combination therapy for treating colorectal cancer in patients with a specific gene mutation.
Bristol Myers added Krazati to its portfolio after it completed an up to $5.8 billion acquisition of Mirati Therapeutics in January .
VR Score
91
Informative language
96
Neutral language
87
Article tone
formal
Language
English
Language complexity
60
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links